Stay updated on Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial
Sign up to get notified when there's something new on the Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial page.

Latest updates to the Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial page
- Check7 days agoChange DetectedReplaced Padua, Italy, 35128 with Padova, Italy, 35128 to reflect the local official name.SummaryDifference0.0%

- Check14 days agoChange DetectedSystemic sclerosis was added as the disease term and Scleroderma removed where it referred to the same condition.SummaryDifference0.0%

- Check21 days agoChange DetectedNapoli, Italy 80138 was updated to Naples, Italy 80138 in the locations list.SummaryDifference0.0%

- Check28 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check36 days agoChange DetectedThe page revision label was updated from v3.4.2 to v3.4.3, limited to version metadata and not affecting study details or user-facing content.SummaryDifference0.0%

- Check57 days agoChange DetectedA Scleroderma topic tag was added, and a link to the Genetic and Rare Diseases Information Center was added to Resources. These changes improve discoverability and provide an additional information source for patients without altering the study details.SummaryDifference0.1%

Stay in the know with updates to Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nintedanib vs Placebo in Scleroderma Lung Fibrosis Clinical Trial page.